Psoriasis treatment - Enstilar Foam (PGD) 60g
Psoriasis treatment - Enstilar Foam (PGD) 60g
Enstilar Foam is a prescription medicine used to treat plaque psoriasis in adults. It is the first and only prescription medication that combines both topical corticosteroids and vitamin D medications in a single spray foam. Corticosteroids reduce inflammation, while topical vitamin D medications slow down the overproduction of skin cells.
This treatment is available only after a consultation with our pharmacist via a private service, called PGD (Patient Group Direction).
A picture of the affected area may facilitate and speed up the processing of your order. This can be sent to email@example.com before or after you place the order.
We may need to identify the intended user with an identity check.
Active ingredients: Each gram contains 50 micrograms of calcipotriol (as monohydrate) and 0.5 mg of betamethasone (as dipropionate).
Excipient with known effect: Butylhydroxytoluene (E321).
Please click here for the full list of ingredients.
Usage and Instructions
Shake the can before use. Spray 1-4 grams of foam holding the can at 3cm from the skin (2-8 seconds of spraying). Spray directly on the affected area or on the hands for application on the scalp. Rub in with your hands/fingertips until fully absorbed. Leave it on the skin all day/night before bathing/showering. Use it once daily for 4 weeks. Wash your hands before/after use. Avoid exposure to sunlight. Read showering instructions on the leaflet for scalp application.
Enstilar is contraindicated in:
- Under 18 years old
- Pregnancy and breastfeeding
- Erythrodermic, exfoliative and pustular psoriasis
- Calcium metabolism disorders
- Viral (e.g. herpes or varicella) lesions of the skin
- Fungal or bacterial skin infections
- Parasitic infections
- Perioral dermatitis
- Atrophic skin
- Striae atrophicae
- Fragility of skin veins
- Acne vulgaris
- Acne rosacea
- Ulcers and wounds
Effects on Endocrine System: Corticosteroid-related adverse effects like adrenocortical suppression or impaired diabetes control may occur with topical corticosteroid use due to systemic absorption. Avoid occlusive dressings and application on large areas, damaged skin, mucous membranes, or skin folds.
Visual Disturbance: Visual issues can result from systemic and topical corticosteroid use. Patients with symptoms like blurred vision should be considered for referral to an ophthalmologist to investigate potential causes, including cataract, glaucoma, or rare conditions like central serous chorioretinopathy (CSCR).
Effects on Calcium Metabolism: Enstilar, containing calcipotriol, may lead to hypercalcaemia. This risk is minimal when not exceeding the maximum daily dose of 15 g.
Local Adverse Reactions: Enstilar contains a potent steroid. Avoid concurrent use of other steroids on the same area, especially on sensitive areas like the face and genitals. Instruct patients to use it correctly and avoid application on the face, mouth, eyes, and wash hands after use.
Concomitant Skin Infections: If lesions become infected, use antimicrobiological therapy. Discontinue corticosteroid treatment if the infection worsens.
Discontinuation of Treatment: When discontinuing topical corticosteroid treatment for psoriasis, be aware of potential rebound effects. Continue medical supervision in the post-treatment period.
Long-term Use: Prolonged corticosteroid use increases the risk of local and systemic adverse reactions. Discontinue treatment in case of such reactions.
Unevaluated Use: Enstilar hasn't been evaluated for guttate psoriasis.
Adverse Reactions to Excipients: Enstilar contains butylhydroxytoluene (E321) as an excipient, which may cause local skin reactions or eye/mucous membrane irritation.
|Infections and Infestations||Uncommon (≥1/1,000 to <1/100)||Folliculitis|
|Immune System Disorders||Uncommon (≥1/1,000 to <1/100)||Hypersensitivity|
|Metabolism and Nutrition Disorders||Uncommon (≥1/1,000 to <1/100)||Hypercalcaemia*|
|Eye Disorders||Not known||Vision, blurred**|
|Skin and Subcutaneous Tissue Disorders||Uncommon (≥1/1,000 to <1/100)||Skin hypopigmentation|
|Not known||Hair colour changes***|
|General Disorders and Administration Site Conditions||Uncommon (≥1/1,000 to <1/100)||Rebound effect|
|Application site pruritus|
|Application site irritation|
|Application site pain****|
|Not known||Application site erythema*****|
*Serum calcium is normalized when treatment is discontinued.
** Information on the frequency of eye disorders is not known.
*** Changes in hair color have been reported, but the frequency is not known.
**** Application site pain includes application site burning.
***** Information on the frequency of application site erythema is not known.